Opus Genetics — Third Quarter 2026 Earnings Summary

Opus Genetics reported a net loss of $46.5 million for the third quarter of 2026, driven by increased research and development expenses and fair value changes in financial instruments. The company's cash position stands at $89.0 million as of September 30, 2026, with projections indicating operations will be funded through 2029. Key pipeline milestones include the completion of dosing for the OPGx-BEST1 Cohort 2 trial, full enrollment of the OPGx-LCA5 Phase 3 trial, and FDA clearance for the OPGx-RDH12 IND application. Additionally, the FDA approved phentolamine ophthalmic solution 0.75% for presbyopia, triggering a regulatory milestone payment from commercial partner Viatris Inc.